Company profile

Avenzo Therapeutics, Inc.

Privately held: no public share price (Still private; a reverse-merger with Nasdaq-listed Rallybio (to trade AVZO) was agreed June 2026 but is not expected to close until Q4 2026. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.businesswire.com/news/home/20260531328050/en/Rallybio-Corporation-and-Avenzo-Therapeutics-Announce-Merger-Agreement-to-Advance-Next-Generation-Oncology-Therapies-and-$215-Million-Concurrent-Private-Placement]) · United States

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
AVZO-021
Phase 2
CDK2Small molecule
HR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
AVZO-023
Phase 2
CDK4Small molecule
HR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
AVZO-1418
Phase 2
EGFR / HER3 (ERBB3) dualSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.